期刊文献+

过氧化物酶体增殖物激活受体γ在大鼠脊髓损伤后继发性损伤中的表达变化 被引量:2

Expression changes of peroxisome proliferator activated receptor γ following secondary injuries in rats with spinal cord injury
原文传递
导出
摘要 目的 观察大鼠脊髓损伤后继发性损伤中过氧化物酶体增殖物激活受体γ(PPARγ)表达的变化.方法 将72只雄性SD大鼠按照随机数字表法分为损伤组(建立大鼠脊髓损伤模型)和对照组(仅显露脊髓,不做打击伤),每组各36只.实时免疫荧光定量多聚酶链反应(FQ-PCR)检测脊髓损伤后1 d、3 d、7 d、14 d、28 d、56 dPPARγmRNA的表达变化,每个时间点取6只大鼠.蛋白印记检测脊髓损伤后1 d、3 d、7 d、14 d、28 d、56 d PPARγ的表达变化.结果 与对照组比较,损伤组脊髓组织中PPARγmRNA和PPARγ表达均明显增加,差异均有统计学意义(P<0.05),其表达高峰在脊髓损伤后14d.结论 脊髓损伤后在继发性损伤中PPARγ的表达明显增加,表达高峰在脊髓损伤后14d. Objective To observe the expression changes of peroxisome proliferator activated receptor γ(PPARγ) following the secondary injuries in rats with spinal cord injury (SCI). Methods Seventy-two male SD rats were equally randomized into control group and SCI group. Real-time fluorescence quantitative polymerase chain reaction (FQ-PCR) was performed to detect the mRNA expression changes of PPARγ on the 1st, 3nd, 7th 14th, 28th and 56th d of SCI. Western blotting wasemployed to detect the protein expression changes of PPARγ Results Compared with those in the control group, the mRNA and protein expressions of PPARγ in the SCI group on the 1st, 3rd, 7th, 14th and 28th d of SCI were significantly increased (P〈0.05), reaching its peak level 14 d after SCI; on the 56th d of SCI, their expression levels in the SCI group were still higher than those in the control group, but no significant differences were noted (P〉0.05). Conclusion The expressions of PPARγare significantly increased following secondary injuries in rats with spinal cord injury, reaching its peak level 14 d after SCI.
出处 《中华神经医学杂志》 CAS CSCD 北大核心 2010年第9期879-882,共4页 Chinese Journal of Neuromedicine
关键词 过氧化物酶体增殖物激活受体 脊髓损伤 继发性损伤 Peroxisome proliferator activated receptor Spinal cord injury Secondary injury
  • 相关文献

参考文献15

  • 1Isseman I,Green S.Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators[J].Nature,1990,347(6294):645-665.
  • 2Craft S,Watson GS.Insulin and neurodegenerative disease:shared and specific mechanisms[J].Lancet Neurol,2004,3(3):169-178.
  • 3Nestrosa NC,Godoy JA,Quintanilla RA,et al.Peroxisome proliferator activated receptory is expressed in hippocampal neurons and itsactivation prevents -amyloidneurodegeneration:role of Wnt signaling[J].Exp Cell Res,2005,304(1):91-104.
  • 4Young W.Spinal cord contusion models.[J].Prog Brain Res,2002,137:23 1-255.
  • 5Mccord JM.Oxygen-derived free radicals in postischemic tissue injury[J].New Eug J Med,1985,312:159.
  • 6Hall ED.Inhibition of lipid peroxidation in CNS trauma[J].J Neurotrauma,1991,8(1):31-40.
  • 7Totoiu MO,Keirstead HS.Spinal cord injury is accompanied by chronic progressive demyelination[J].J Comp Neurol,2005,486(4):373-383.
  • 8Ricote M,Li AC,Willson TM,et al.The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation.[J].Nature,1998,391(6662):79-82.
  • 9Jiang C,Ting AT,Seed B.PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines[J] Nature,1998,391(6662):82-86.
  • 10Petrova TV,Akama KT,Van Eldik LJ.Cyclopentenone prostaglandins suppress activation of microglia:down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta 12,14-prostaglandin J2[J].Proc Natl Acad Sci U S A,1999,96(8):4668-4673.

同被引文献24

  • 1Tyagi S, Gupta P, Saini AS, et al. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases [J]. Adv Pharm Technol Res, 2011,2(4): 236-240.
  • 2Mandard S, Patsouris D. Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors [J]. PPAR Res, 2013: 1-23.
  • 3Burch R, Wells R. Pathophysiology of migraine [J]. Headache, 2013, 53(2): 420-422.
  • 4Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat [J]. Brain Res, 1995, 6820-2): 167-181.
  • 5Crisafulli C, Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages [J]. Shock, 2009, 32(I): 62-73.
  • 6Defaux A, Zurich MG, Braissant O, et al. Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination[J]. Neuroinflammation, 2009, 6: 15.
  • 7Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Thl differentiation [J]. Genes Immun, 2002, 3(2): 59-70.
  • 8Sato T, Hanyu H, Hirao K, et al. Efficacy of PPAR-y agonist pioglitazone in mild Alzheimer disease [J]. Neurobiol Aging, 2011, 32(9): 1626-1633.
  • 9Stovner LJ,Andree C. Prevalence of headache in Europe:a review for the Eurolighttproject[J].{H}JOURNAL OF HEADACHE AND PAIN,2010.289-299.
  • 10Tyagi S,Gupta P,Saini AS. The peroxisome proliferator-activated receptor:A family of nuclear receptors role in various diseases[J].J Adv Pharm Technol Res,2011.236-240.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部